SCHEMBL2756576

SCHEMBL2756576

CCc1ccc2ccc(CC)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2A6 P11509 1/20 0.47
ELANE P08246 2/20 0.44
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TRPA1 O75762 1/20 0.39
TERT O14746 1/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 3/20 0.38
HPGD P15428 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NOS3 P29474 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7833593 0.86 HSD17B10 (0.45) CYP1A2CYP2A6ELANETERTHSD17B10
SCHEMBL12824284 0.86 CYP1A2 (0.50) CYP1A2CYP2A6ELANENPC1RAB9A
SCHEMBL14439066 0.80 CYP1A2 (0.52) CYP1A2CYP2A6ELANENPC1RAB9A
SCHEMBL12044582 0.79 CYP1A2 (0.57) CYP1A2CYP2A6NPC1RAB9AKDM4E
SCHEMBL16284370 0.79 CYP1A2 (0.57) CYP1A2CYP2A6ELANETERTALDH1A1
SCHEMBL17179265 0.78 PDE10A (0.45) CYP1A2CYP2A6TERTKMT2AKDM4E
SCHEMBL13878246 0.78 NR4A2 (0.46) TERTMEN1KMT2APOLB
SCHEMBL17179408 0.78 BACE1 (0.52) CYP1A2CYP2A6TERTALDH1A1MEN1
SCHEMBL12516490 0.78 TERT (0.50) CYP1A2ELANETERTALDH1A1MEN1
SCHEMBL16284375 0.78 TERT (0.37) CYP1A2TERTMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896443-B2 Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof PETER MACCALLUM CANCER INSTITUTE (AU) 2018-02-20 US disclosed
EP-3159345-A1 INHIBITORS OF HEPATITIS C VIRUS Gilead Sciences, Inc. (US) 2017-04-26 EP disclosed
EP-2861604-B1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES INC (US) 2017-03-01 EP disclosed
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2015-08-06 US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-20100298388-A1 SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD. (GB) 2010-11-25 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 CYP1A2 383/4885CYP2A6 892/4885ELANE 1818/4885
US-20100298388-A1 SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS ALK, CBR3, CBR1 CYP1A2 718/4885CYP2A6 739/4885ELANE 1872/4885
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PRF1, GZMB, BAK1 CYP1A2 2826/4885CYP2A6 1481/4885ELANE 205/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 CYP1A2 383/4885CYP2A6 892/4885ELANE 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.